News

Leqembi's Surge: JPY 10 Billion Revenue in Q3 2024

Leqembi's Surge: JPY 10 Billion Revenue in Q3 2024

Leqembi Achieves Significant Revenue Growth

In an impressive financial performance, BioArctic AB's partner, Eisai, announced that global revenue for Leqembi reached JPY 10 billion in the most recent quarter. This milestone marks a remarkable increase of roughly 60% compared to the previous quarter, where revenue stood at JPY 6.3 billion. As a result, BioArctic is set to receive approximately SEK 70 million in royalties, indicating a prosperous collaboration amid the ongoing battle against Alzheimer's disease.

The Collaborative Effort Behind Leqembi

The development and regulatory processes for Leqembi are led by Eisai, who, together with Biogen, is co-commercializing and promoting this cutting-edge treatment. Eisai retains the ultimate authority when it comes to key decision-making. Meanwhile, BioArctic stays focused on its strategic rights to commercialize lecanemab in the Nordic region. With the anticipated European approval, both Eisai and BioArctic are gearing up for a joint commercialization effort, emphasizing their commitment to enhancing patient access to this innovative therapy.

Upcoming Financial Reporting

Investors and stakeholders can look forward to additional insights as BioArctic plans to release its financial report for the third quarter of 2024. The scheduled publication is set for November 14 at 08:00 a.m. CET, a date that has added weight given the promising revenue figures announced.

About Lecanemab (Leqembi)

Lecanemab is an innovative humanized IgG1 monoclonal antibody specifically designed to target both soluble protofibril and insoluble aggregates of amyloid-beta (A?). A significant breakthrough in Alzheimer's treatment, lecanemab is currently approved in multiple countries, demonstrating its efficacy in managing Mild Cognitive Impairment (MCI) due to Alzheimer's disease and mild Alzheimer's dementia. Its approvals were heavily reliant on the positive outcomes of Eisai's global Clarity AD clinical trial.

Clinical Data and Adverse Events

The Phase 3 clinical trial of lecanemab met all primary and secondary endpoints with statistically significant results. However, as with any treatment, awareness of adverse events is crucial. The most commonly reported adverse events (over 10% incidence) among patients receiving lecanemab included infusion reactions, ARIA-H, ARIA-E, headaches, and falls. These results underscore the importance of ongoing monitoring and patient education regarding potential side effects.

Future Directions and Research

Since July 2020, Eisai has been conducting a Phase 3 clinical study, AHEAD 3-45, which explores the effects of lecanemab on individuals diagnosed with preclinical Alzheimer's disease. This study exemplifies a public-private partnership aimed at improving treatment pathways for Alzheimer's patients. Moreover, the Tau NexGen clinical study has been initiated for individuals with Dominantly Inherited Alzheimer's Disease (DIAD), further solidifying lecanemab's position as a cornerstone in anti-amyloid therapies.

BioArctic's Legacy and Commitment

BioArctic established its long-term collaboration with Eisai back in 2005, focusing on advancing treatments for Alzheimer’s disease. The strategic agreements and ongoing projects demonstrate BioArctic's commitment to innovating solutions that delay or halt the progression of neurodegenerative diseases. With a robust portfolio that includes treatments for Parkinson’s disease and ALS, BioArctic is not just stopping at lecanemab. Their proprietary BrainTransporter™ technology holds future promise for delivering even more breakthrough therapies across the blood-brain barrier.

Frequently Asked Questions

What is Leqembi?

Leqembi, also known as lecanemab, is a monoclonal antibody treatment targeting amyloid-beta, approved for Alzheimer's-related cognitive decline.

How much revenue did Leqembi generate in Q3 2024?

Leqembi generated approximately JPY 10 billion in revenue during the third quarter, marking a 60% increase from the previous quarter.

Who are the partners involved in Leqembi's commercialization?

Eisai and Biogen collaboratively commercialize Leqembi, while BioArctic holds rights to the Nordic region.

When will BioArctic's Q3 2024 report be released?

The report is scheduled for publication on November 14 at 08:00 a.m. CET.

What are the common side effects of Leqembi?

Common side effects include infusion reactions and ARIA conditions, which require close monitoring and proper patient education.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Step Inside Henson's Creature Shop Magic in NYC

Updated Category News Views 1

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Continue Reading
AI Trust in Finance: Survey Reveals Market Impact

Updated Category News Views 2

Trust in AI for Financial Guidance: Where Are We Headed? The market winds shift with every sunrise, and today’s buzzword? Artificial Intelligence. You’d almost think AI’s trying to steal my job along with every other trader’s mojo. But here's the twist—A survey from Possible Finance shows about 15% of folks would actually lean on AI for their financial advice....

Continue Reading
Red-Eye Flights Surge, Driven By Western U.S. Routes

Updated Category News Views 3

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Continue Reading
Navigating Land Access: The Hidden Roadblock in Mining

Updated Category News Views 2

Mining's Often Overlooked Obstacle: Land Access In the world of mining, the shallow thrills of striking gold are often overshadowed by the frustrating slog of securing land access. You can have your permits lined up, your finances sorted, and drills humming along, but if you haven’t sweet-talked the folks farming above your visible vein of riches, you could be staring...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 1

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
BusyBee AI Revolutionizes Classroom Feedback Efficiency

Updated Category News Views 1

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

Continue Reading
Flex Dental Solutions Adds BNPL, Surcharging to FlexPayments

Updated Category News Views 2

Diving into Dental Finances: A New Moneymaker? It's about time someone shook up the dental payment scene, and Flex Dental Solutions seems to be the one doing it. They rolled out some intriguing new features for their FlexPayments platform aimed squarely at dental practices using Open Dental. What we're seeing here is their attempt to bridge a couple of financial headaches...

Continue Reading
OneAscent Welcomes Monica Stoudemire as New CCO

Updated Category News Views 2

New Leadership in Compliance Diving straight into the tumultuous sea of securities compliance, OneAscent's got a fresh captain at the helm. Monica Stoudemire's stepped into the Chief Compliance Officer's shoes with a track record that'd make any investor breathe a sigh of relief. After all, blending two decades of on-the-ground experience with regulatory acumen ain't...

Continue Reading
Crystal Risotti: Leading IT Compliance in Healthcare

Updated Category News Views 1

A Journey Marked by Dedication and Expertise In the demanding world of healthcare technology, where regulations can make or break a company, Crystal Risotti has carved out a space for herself as a leader. Over the last 30 years, she's developed a reputation for blending regulatory expertise with practical business strategies. Her recognition as a Pinnacle Professional of...

Continue Reading
Diaper Affordability: A Hidden Crisis, Taxpayer Burden

Updated Category News Views 6

A Silent Crisis Lurking in Diapers Diapers. We don’t think about them much until we need them, but nearly half of U.S. families are painfully aware of their cost. According to a report from the NDBN Diaper Check 2026, many struggle to meet this basic necessity. This isn't just about keeping babies clean—it's a public health issue with economic ripples Congress can't...

Continue Reading

Top 5 Most Recently Viewed Articles

Curve Therapeutics Welcomes New Leadership Members to Drive Innovation

Updated Category News Views 251

Curve Therapeutics Welcomes New Leadership Members to Drive Innovation Curve Therapeutics is excited to announce important additions to its leadership team, appointing Andre Hoekema as Chair of the Board and Cora Griffin as Head of Business Development. This strategic move is aimed at reinforcing the company's ambitious goals and expanding its innovative therapeutic...

Continue Reading
Unlocking RMB's Potential: Hong Kong's Strategic Role

Updated Category News Views 284

How Hong Kong Can Lead in RMB Internationalization In recent discussions, the focus has been on how Hong Kong can enhance its position in the global finance landscape by embracing the internationalization of the Renminbi (RMB). Stephen Law Cheuk-kin, a highlighted member of the National Committee of the CPPCC, emphasized the importance of Hong Kong in this transformative...

Continue Reading
Significant Growth and Strategic Moves at Park Street A/S

Updated Category News Views 201

Overview of Park Street A/S's Interim Financial Report Park Street A/S has made notable strides in its financial and strategic performance during the first half of 2025. Financial Performance Highlights In the first half of 2025, Park Street A/S reported an EBVAT of DKK 13.7 million, a dramatic increase from DKK 6.5 million in the same period of the previous year. The...

Continue Reading
Invesco Mortgage Capital Declares Quarterly Cash Dividend Today

Updated Category News Views 150

Invesco Mortgage Capital Announces Dividend for Shareholders Invesco Mortgage Capital Inc. (NYSE: IVR) recently shared some exciting news with its investors. The company's Board of Directors has declared a cash dividend of $0.34 per share for the second quarter of the current fiscal year. This announcement reflects the company's ongoing commitment to delivering value to...

Continue Reading
ExoraPad's $EXP Token Presale: A Game-Changer for XRP

Updated Category News Views 478

Exciting Developments in Crypto: The ExoraPad $EXP Token Launch The much-anticipated presale of the $EXP token, conducted by ExoraPad, is set to create significant waves in the crypto community. This event, scheduled for an upcoming date, is generating buzz among XRP enthusiasts. The presale aims to offer investors a unique opportunity to diversify their portfolios and...

Continue Reading